Averitas Pharma, a recently acquired Grunenthal Group company, has acquired the United States commercialisation rights for Qutenza
(capsaicin) eight% after the acquisition of the product by Grunenthal on the same day, it was reported yesterday.
Averitas Pharma will be enhancing the commercial distribution model for Qutenza
towards a specialty pharmacy and hub services model that makes it easier for patients to access the product and support health care professionals in prescribing and applying it.
German science-focused pharmaceutical company Grunenthal revealed on Monday that it has acquired additional global commercial rights for the dermal pain patch Qutenza
(8% capsaicin) from Acorda Therapeutics Inc (USA).
: a capsaicin 8% patch for the management of postherpetic neuralgia.
Patients were excluded (n = 48) if they were found not to suffer from PNP, a Qutenza
patch was previously used, the medical file was incomplete, and the follow-up was missing.
/ additional global commercial rights
 European Medicines Agency, Human Medicines deailed information for Qutenza
, Capsaicin, http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000909/ human_med_001008.jsp&mid=WC0b01ac058001d124.
Efficacy of Qutenza* (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza
Clinical Trials Database.
M2 EQUITYBITES-November 8, 2018-GrA1/4nenthal Acquires Global Rights for Dermal Pain Patch Qutenza
M2 PHARMA-December 14, 2016-Grunenthal to acquire Qutenza
European commercialisation rights
13 December 2016 - German drugmaker GrA1/4nenthal Group has entered into a definitive agreement with Japanese drugmaker Astellas Pharma Inc's Astellas Pharma Europe Ltd subsidiary for the exclusive rights to the dermal patch Qutenza
(capsaicin 8%) in Europe, Middle East and Africa, the company said.
M2 EQUITYBITES-November 5, 2018-GrA1/4nenthal announces acquisition of additional global commercial rights for dermal pain patch Qutenza
from Acorda Therapeutics
-GRUNENTHAL TO ACQUIRE COMMERCIALISATION EMEE RIGHTS OF ASTELLAS' QUTENZA
Biotechnology company Acorda Therapeutics Inc (Nasdaq:ACOR) revealed on Tuesday that it has completed its acquisition of two neuropathic pain management assets, Qutenza
and NP-1998, from NeurogesX Inc (OTC Markets:NGSX).